Logo image of LSTA

LISATA THERAPEUTICS INC (LSTA) Stock Fundamental Analysis

NASDAQ:LSTA - Nasdaq - US1280583022 - Common Stock - Currency: USD

2.43  +0.03 (+1.25%)

Fundamental Rating

2

LSTA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. While LSTA seems to be doing ok healthwise, there are quite some concerns on its profitability. LSTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LSTA had negative earnings in the past year.
LSTA had a negative operating cash flow in the past year.
In the past 5 years LSTA always reported negative net income.
LSTA had a negative operating cash flow in each of the past 5 years.
LSTA Yearly Net Income VS EBIT VS OCF VS FCFLSTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

LSTA has a Return On Assets (-57.10%) which is comparable to the rest of the industry.
LSTA has a Return On Equity (-67.58%) which is in line with its industry peers.
Industry RankSector Rank
ROA -57.1%
ROE -67.58%
ROIC N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
LSTA Yearly ROA, ROE, ROICLSTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

LSTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSTA Yearly Profit, Operating, Gross MarginsLSTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

6

2. Health

2.1 Basic Checks

LSTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LSTA has been increased compared to 1 year ago.
The number of shares outstanding for LSTA has been increased compared to 5 years ago.
There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LSTA Yearly Shares OutstandingLSTA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
LSTA Yearly Total Debt VS Total AssetsLSTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -20.70, we must say that LSTA is in the distress zone and has some risk of bankruptcy.
LSTA has a Altman-Z score of -20.70. This is amonst the worse of the industry: LSTA underperforms 86.00% of its industry peers.
There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.7
ROIC/WACCN/A
WACC9.03%
LSTA Yearly LT Debt VS Equity VS FCFLSTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

LSTA has a Current Ratio of 6.16. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LSTA (6.16) is better than 61.76% of its industry peers.
A Quick Ratio of 6.16 indicates that LSTA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.16, LSTA is in the better half of the industry, outperforming 62.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.16
Quick Ratio 6.16
LSTA Yearly Current Assets VS Current LiabilitesLSTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

LSTA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.50%.
EPS 1Y (TTM)6.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

LSTA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.01% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.78%
EPS Next 2Y23.02%
EPS Next 3Y15.98%
EPS Next 5Y10.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSTA Yearly Revenue VS EstimatesLSTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2022 2024 2027 2029 2030 2031 50M 100M 150M 200M
LSTA Yearly EPS VS EstimatesLSTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSTA. In the last year negative earnings were reported.
Also next year LSTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSTA Price Earnings VS Forward Price EarningsLSTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSTA Per share dataLSTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as LSTA's earnings are expected to grow with 15.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.02%
EPS Next 3Y15.98%

More info and screens

0

5. Dividend

5.1 Amount

LSTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LISATA THERAPEUTICS INC

NASDAQ:LSTA (6/18/2025, 8:04:09 PM)

2.43

+0.03 (+1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-11 2025-08-11
Inst Owners9.11%
Inst Owner Change-0.3%
Ins Owners7.36%
Ins Owner Change20.72%
Market Cap20.90M
Analysts82.22
Price Target17 (599.59%)
Short Float %0.41%
Short Ratio2.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.96%
Min EPS beat(2)22.88%
Max EPS beat(2)29.05%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)12.1%
Max EPS beat(4)29.05%
EPS beat(8)8
Avg EPS beat(8)22.61%
EPS beat(12)10
Avg EPS beat(12)-44.49%
EPS beat(16)13
Avg EPS beat(16)-35.84%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.96%
PT rev (3m)-1.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)4.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.9
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-2.3
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-2.25
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0.12
BVpS3.44
TBVpS3.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.1%
ROE -67.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.16
Quick Ratio 6.16
Altman-Z -20.7
F-Score4
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.38%
EPS Next Y6.78%
EPS Next 2Y23.02%
EPS Next 3Y15.98%
EPS Next 5Y10.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.69%
EBIT Next 3Y-12.88%
EBIT Next 5Y-7.46%
FCF growth 1Y3.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.37%
OCF growth 3YN/A
OCF growth 5YN/A